GLUE

Over the past six months, Monte Rosa Therapeutics' stock has experienced significant price appreciation. The stock price increased significantly over the last 12 months and year-to-date as of May 7, 2026. Monte Rosa reported a Q4 2025 revenue that missed estimates and a Q1 2026 net loss with collaboration revenue falling due to the normalization of milestone payments. Positive interim data from a Phase 1 clinical study of MRT-8102 showed a reduction in CRP levels, and preclinical data for a novel cyclin E1-directed MGD was presented. The company anticipates initiating multiple Phase 2 studies for MRT-8102 and MRT-2359 in 2026-2027, and MRT-6160 is advancing towards Phase 2 study initiations by Novartis. Monte Rosa closed a $345 million equity offering, boosting its financial reserves, and analysts have given the stock a consensus rating of "Moderate Buy" with a significant upside from its current price. Technical indicators showed a shift to an upward trend in April 2026.